...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >In vivo High-Content Screening in Zebrafish for Developmental Nephrotoxicity of Approved Drugs
【24h】

In vivo High-Content Screening in Zebrafish for Developmental Nephrotoxicity of Approved Drugs

机译:在斑马鱼的体内高含量筛选中批准药物的发育肾毒性

获取原文

摘要

Despite widespread drug exposure, for example during gestation or in prematurely born children, organ-specific developmental toxicity of most drugs is poorly understood. Developmental and functional abnormalities are a major cause of kidney diseases during childhood; however, the potential causal relationship to exposure with nephrotoxic drugs during nephrogenesis is widely unknown. To identify developmental nephrotoxic drugs in a large scale, we established and performed an automated high-content screen to score for phenotypic renal alterations in the Tg(wt1b:EGFP) zebrafish line. During early nephrogenesis, embryos were exposed to a compound library of approved drugs. After treatment, embryos were aligned within microtiter plates using 3D-printed orientation tools enabling the robust acquisition of consistent dorsal views of pronephric kidneys by automated microscopy. To qualitatively and quantitatively score and visualize phenotypes, we developed software tools for the semi-automated analysis, processing and visualization of this large image-based dataset. Using this scoring scheme, we were able to categorize compounds based on their potential developmental nephrotoxic effects. About 10% of tested drugs induced pronephric phenotypes including glomerular and tubular malformations, or overall changes in kidney morphology. Major chemical compound groups identified to cause glomerular and tubular alterations included dihydropyridine derivatives, HMG CoA reductase inhibitors, fibrates, imidazole, benzimidazole and triazole derivatives, corticosteroids, glucocorticoids, acetic acid derivatives and propionic acid derivatives. In conclusion, the presented study demonstrates the large-scale screening of kidney-specific toxicity of approved drugs in a live vertebrate embryo. The associated technology and tool-sets can be easily adapted for other organ systems providing a unique platform for in vivo large-scale assessment of organ-specific developmental toxicity or other biomedical applications. Ultimately, the presented data and associated visualization and browsing tools provide a resource for potentially nephrotoxic drugs and for further investigations.
机译:尽管普遍存在的药物暴露,例如在妊娠期或过早出生的儿童期间,大多数药物的器官特异性发育毒性都很差。发育和功能异常是童年期间肾病的主要原因;然而,在肾发生器中与肾毒性药物暴露的潜在因果关系是广泛的未知。为了鉴定大规模的发育肾毒性药物,我们建立并进行了自动化的高含量筛网以得分为TG(WT1B:EGFP)斑马鱼系中的表型肾改变。在早期肾发生期间,将胚胎暴露于批准的药物的复合文库中。处理后,使用3D印刷取向工具在微量滴定板内对齐胚胎,使自动显微镜通过自动显微镜稳健地获取静脉肾的一致背面视图。为了定性和定量分数和可视化表型,我们开发了用于半自动分析,处理和可视化的基于大图像的数据集的软件工具。使用该评分方案,我们能够根据其潜在的发育肾毒性效应进行分类化合物。大约10%的测试药物诱导静脉表型,包括肾小球和管状畸形,或肾脏形态的总体变化。鉴定为引起肾小球和管状改变的主要化学化合物包括二氢吡啶衍生物,HMG CoA还原酶抑制剂,匹配,咪唑,苯并咪唑和三唑衍生物,皮质类固醇,糖皮质激素,乙酸衍生物和丙酸衍生物。总之,本研究表明,在活脊椎动物胚胎中批准药物的肾脏特异性毒性大规模筛查。相关技术和工具集可以容易地适应其他器官系统,为器官特异性发育毒性或其他生物医学应用提供独特的平台。最终,所提出的数据和相关的可视化和浏览工具为潜在的肾毒性药物提供资源,并进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号